BGOG-ov81/VS-6766-301

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Open
Trial drug
Avutometinib, Defactinib
Grade
Low grade
Prior lines
1, 2, 3, 4, >4
Histology
Serous
Platin
Platinum sensitive
Platinum resistant
Secondary platinum refractory
Phase
III

Treatment

This study consists of two different treatment options:

  • Avutometinib + Defactinib
  • Standard therapy (Caelyx, Paclitaxel, Topotecan, Anastrazole or Letrozole)

Avutometinib is administered as a tablet twice per week. 
Defactinib is administred as a tablet twice daily.
Caelyx is administered intravenously every 4 weeks. 
Paclitaxel and Topotecan are administered intravenously on three subsequent weeks, followed by a week off. 
Anastrazole and Letrozole are administered daily as a tablet.

You will be randomly allocated to one of the treatment groups. In case you are randomized to the group receiving standard therapy your treating physician will decide which of the drugs is best suited for you.

Treatment duration

The treatments can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.